1,478 results on '"Chapple, C."'
Search Results
2. Overview of Diagnosis and Pharmacological Treatment of Overactive and Underactive Bladder Disorders
3. Role of Surgery in Bladder Pain Syndrome
4. Overview of Diagnosis and Pharmacological Treatment of Overactive and Underactive Bladder Disorders
5. Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms
6. Particulate Versus Non-Particulate Bulking Agents In The Treatment Of Stress Urinary Incontinence
7. Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED
8. Predicting prostate surgery outcome from standard clinical assessments of lower urinary tract symptoms to derive prognostic symptom and flowmetry criteria
9. Are sports foods all they shake up to be? Understanding the formulated supplementary sports foods retail environment: A product audit of availability, nutrient profile, and claims
10. The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials
11. Failure of Urinary Drainage: Lower Tract
12. OnabotulinumtoxinA Is Efficacious and Well Tolerated in Male Patients With Overactive Bladder and Urinary Incontinence: Placebo-Controlled Treatment Cycle 1 Results From a Pooled Analysis of Four Randomized Trials
13. The Semon Lectures and the foundation of modern ENT
14. Is Pharmacotherapy a Satisfactory Alternative Treatment for Benign Prostatic Hyperplasia?
15. The Investigation of Benign Prostatic Hyperplasia
16. Introduction: The Clinical Problem
17. Pathophysiological Changes in the Obstructed Bladder
18. Anatomy and Innervation of the Prostate Gland
19. The Physiology of Micturition
20. The Anatomy and Innervation of the Bladder
21. LOWER URINARY TRACT SYMPTOMS AS RISK FACTOR FOR CARDIOVASCULAR EVENTS IN MEN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF FIVE LONGITUDINAL TRIALS: MP35-03
22. The Semon Lectures and the foundation of modern ENT.
23. Nocturia: risk factors and associated comorbidities; findings from the EpiLUTS study
24. Is Pharmacotherapy for Benign Prostatic Hyperplasia an Alternative?
25. Are Metallic Endourological Stents an Alternative to Prostatectomy in the Management of Benign Prostatic Hyperplasia?
26. Syringa vulgaris L. (Common Lilac): In Vitro Culture and the Occurrence and Biosynthesis of Phenylpropanoid Glycosides
27. Functional and radioligand binding characterization of the α1L-adrenoceptor subtype of the human vas deferens
28. Tissue engineered buccal mucosa for urethroplasty: Progress and future directions☆
29. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies
30. Root Structure in the Fern Platycerium bifurcatum (Cav.) C. Chr. (Polypodiaceae)
31. Inkontinenz im Alter: Was kann und soll man tun?
32. Pattern of distribution of Prevotella species/phylotypes associated with healthy gingiva and periodontal disease
33. Symptoms suggestive of urinary tract infection rates among intermittent urinary catheter users: Real-world evidence research based on a longitudinal patient database in the UK
34. Editorial Comment
35. Validation of Treatment Benefit Scale for Assessing Subjective Outcomes in Treatment of Overactive Bladder
36. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
37. Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial
38. Contemporary issues with pharmacotherapy for lower urinary tract symptoms
39. Urgency and pain in patients with overactive bladder and bladder pain syndrome. What are the differences?
40. Phase II Study on the Efficacy and Safety of the EP1 Receptor Antagonist ONO-8539 for Nonneurogenic Overactive Bladder Syndrome
41. The burden of urgency urinary incontinence on health and wellbeing
42. CAN METABOLIC SYNDROME AFFECT THE EFFICACY OUTCOMES OF COMBINATION THERAPY WITH DAILY TADALAFIL 5MG PLUS TAMSULOSIN 0.4MG IN MEN WITH LUTS AND ED?
43. Current issues in managing men with lower urinary tract symptoms in primary care
44. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis
45. Evaluation and Treatment of Lower Urinary Tract Symptoms in Older Men
46. Nocturia: current concepts and future perspectives
47. Urinary incontinence – a challenge to the physiologist Joint symposium for the EU/FP7 networks INComb and TRUST in collaboration with the Swedish Enuresis Academy (SEA), Stockholm 2011
48. Future drugs for the treatment of benign prostatic hyperplasia
49. Oxybutynin and the overactive bladder
50. Which muscarinic receptor is important in the bladder?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.